A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Impact of Age and Comorbidities on Treatment Outcomes of First-line Treatment With Palbociclib in Combination With an Aromatase Inhibitor (AI) in Patients Diagnosed With HR+/HER2 - Metastatic Breast Cancer - Danish Non-Interventional Study

The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer. The study will consider participants who:

• have advanced or metastatic breast cancer that is spread to other parts of the body.

• have HR+/HER2- (hormone receptor positive* / human epidermal growth factor receptor 2 negative**) breast cancer types.

  • Hormone receptor positive (HR+): are cells that have a group of proteins that bind to a specific hormone. For example, some breast cancer cells have receptors for the hormones estrogen or progesterone.

These cells are hormone receptor positive, and they need estrogen or progesterone to grow. This can affect how the cancer is treated. Knowing if the cancer is hormone receptor positive may help plan treatment.

• Human epidermal growth factor receptor 2 negative (HER2-): cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2 negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface. Checking to see if a cancer is HER2 negative may help plan treatment.

  • have started treatment in the period between January 2017 and December 2021.

The study will describe the treatment effect for different patient groups in terms of age and comorbidities. Comorbidity is the condition of having two or more diseases at the same time. The data is collected by the Danish Breast Cancer Group in the period between 2017 to 2023.

Study Overview

• Status: Completed
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: Palbociclib in combination with AI

• Study Type: Observational
• Enrollment (Actual): 1

Contacts and Locations

Study Locations

• Denmark
  • Copenhagen, Denmark, 2100
    • Copenhagen University Hospital, Rigshospitalet

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

The full dataset consists of endocrine sensitive, endocrine resistant and de novo HR+/HER2- mBC patients treated with palbociclib as first-line treatment (01 January 2017- 31 December 2021). Patients will be censored for OS and PFS by 31 December 2023.

Description

Inclusion Criteria:

• Patients with breast cancer (ICD-10: C50)
• A diagnosis of HR+/HER2- locally advanced or metastatic breast cancer
• Endocrine sensitive, endocrine resistant, or de novo mBC patient
• Inclusion date: Date of relapse/stage IV disease/progression leading to initiation of palbociclib+AI

Exclusion Criteria:

• There are no exclusion criteria for this study

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Palbociclib in combination with AI; Patients with HR+/HER2- locally advanced or metastatic breast cancer treated with palbociclib in combination with AI, in Denmark.	Drug: Palbociclib in combination with AI; Patients with HR+/HER2- locally advanced or metastatic breast cancer treated with palbociclib in combination with AI as first-line treatment, in Denmark.; Other Names: Ibrance

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free Survival (PFS) of all mBC patients receiving palbociclib in combination with AI as first-line treatment	PFS is defined as the date of relapse or stage IV disease (index date) to progression or death, whichever occurs first.; Patients will be censored for PFS by 31 December 2023; Progression of disease is based on scans and blood testing results.	01 Jan 2017 - 31 Dec 2023
Overall Survival (OS) of all mBC patients receiving palbociclib in combination with AI as first-line treatment	OS is defined as the date of relapse or stage IV disease (index date) until death of any cause. - Patients will be censored for OS by 31 December 2023.	01 Jan 2017 - 31 Dec 2023

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Age distribution in the full data set of mBC patients receiving palbociclib + AI as first-line treatment		01 Jan 2017 - 31 Dec 2023
PFS in mBC patients below 65 years of age receiving palbociclib + AI as first-line treatment	PFS is defined as the date of relapse or stage IV disease (index date) to progression or death, whichever occurs first.; Patients will be censored for PFS by 31 December 2023; Progression of disease is based on scans and blood testing results.	01 Jan 2017 - 31 Dec 2023
PFS in mBC patients between 65-74 years of age receiving palbociclib + AI as first-line treatment	PFS is defined as the date of relapse or stage IV disease (index date) to progression or death, whichever occurs first.; Patients will be censored for PFS by 31 December 2023; Progression of disease is based on scans and blood testing results.	01 Jan 2017 - 31 Dec 2023
PFS in mBC patients 75+ years of age receiving palbociclib + AI as first-line treatment	PFS is defined as the date of relapse or stage IV disease (index date) to progression or death, whichever occurs first.; Patients will be censored for PFS by 31 December 2023; Progression of disease is based on scans and blood testing results.	01 Jan 2017 - 31 Dec 2023
OS in mBC patients below 65 years of age receiving palbociclib + AI as first-line treatment	OS is defined as the date of relapse or stage IV disease (index date) until death of any cause. - Patients will be censored for OS by 31 December 2023.	01 Jan 2017 - 31 Dec 2023
OS in mBC patients between 65-74 years of age receiving palbociclib + AI as first-line treatment	OS is defined as the date of relapse or stage IV disease (index date) until death of any cause. - Patients will be censored for OS by 31 December 2023.	01 Jan 2017 - 31 Dec 2023
OS in mBC patients 75+ years of age receiving palbociclib + AI as first-line treatment	OS is defined as the date of relapse or stage IV disease (index date) until death of any cause. - Patients will be censored for OS by 31 December 2023.	01 Jan 2017 - 31 Dec 2023
PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into Charlson Comorbidity Index (CCI) point score of 0	Patients with a CCI score of 0 defines patients with no comorbidity besides the breast cancer disease	01 Jan 2017 - 31 Dec 2023
PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into CCI point score of 1	Patients with a CCI score of 1 defines patients with one comorbidity of the type with a score of 1, e.g., myocardial infarction or diabetes mellitus.	01 Jan 2017 - 31 Dec 2023
PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into CCI point score of 2	Patients with a CCI score of 2 defines patients with two comorbidities each having a score of 1 or one comorbidity alone with a CCI score of 2, e.g., diabetes mellitus with organ damage or a solid tumor besides breast cancer disease.	01 Jan 2017 - 31 Dec 2023
PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into CCI point score of 3 or higher (3+)	Patients with a CCI score of 3 or higher (3+) defines patients with severe comorbidity/ies having one comorbidity with a CCI score of 6, e.g., HIV/AIDS, or two or more comorbidities each with CCI scores of 1-2. These comorbidities are also besides the patients' breast cancer disease.	01 Jan 2017 - 31 Dec 2023
OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into CCI point score of 0	Patients with a CCI score of 0 defines patients with no comorbidity besides the breast cancer disease	01 Jan 2017 - 31 Dec 2023
OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into CCI point score of 1	Patients with a CCI score of 1 defines patients with one comorbidity of the type with a score of 1, e.g., myocardial infarction or diabetes mellitus.	01 Jan 2017 - 31 Dec 2023
OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into CCI point score of 2	Patients with a CCI score of 2 defines patients with two comorbidities each having a score of 1 or one comorbidity alone with a CCI score of 2, e.g., diabetes mellitus with organ damage or a solid tumor besides breast cancer disease.	01 Jan 2017 - 31 Dec 2023
OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into CCI point score of 3 or higher (3+)	Patients with a CCI score of 3 or higher (3+) defines patients with severe comorbidity/ies having one comorbidity with a CCI score of 6, e.g., HIV/AIDS, or two or more comorbidities each with CCI scores of 1-2. These comorbidities are also besides the patients' breast cancer disease.	01 Jan 2017 - 31 Dec 2023
PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment no comorbidity	No comorbidity from the five main disease groups: Cardiac disease, Vascular disease, Metabolic disease, Psychiatric disease, Blood and lymphatic system.	01 Jan 2017 - 31 Dec 2023
PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment one comorbidity	One comorbidity from the five main disease groups: Cardiac disease, Vascular disease, Metabolic disease, Psychiatric disease, Blood and lymphatic system.	01 Jan 2017 - 31 Dec 2023
PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment with two or more comorbidities	Two or more comorbidities from the five main disease groups: Cardiac disease, Vascular disease, Metabolic disease, Psychiatric disease, Blood and lymphatic system.	01 Jan 2017 - 31 Dec 2023
OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment no comorbidity	No comorbidity from the five main disease groups: Cardiac disease, Vascular disease, Metabolic disease, Psychiatric disease, Blood and lymphatic system.	01 Jan 2017 - 31 Dec 2023
OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment one comorbidity	One comorbidity from the five main disease groups: Cardiac disease, Vascular disease, Metabolic disease, Psychiatric disease, Blood and lymphatic system.	01 Jan 2017 - 31 Dec 2023
OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment with two or more comorbidities	Two or more comorbidities from the five main disease groups: Cardiac disease, Vascular disease, Metabolic disease, Psychiatric disease, Blood and lymphatic system.	01 Jan 2017 - 31 Dec 2023
PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Cardiac disease	PFS is defined as the date of relapse or stage IV disease (index date) to progression or death, whichever occurs first.; Patients will be censored for PFS by 31 December 2023; Progression of disease is based on scans and blood testing results. Comorbidity: Cardiac disease	01 Jan 2017 - 31 Dec 2023
PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Vascular disease	PFS is defined as the date of relapse or stage IV disease (index date) to progression or death, whichever occurs first.; Patients will be censored for PFS by 31 December 2023; Progression of disease is based on scans and blood testing results. Comorbidity: Vascular disease	01 Jan 2017 - 31 Dec 2023
PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Metabolic disease	PFS is defined as the date of relapse or stage IV disease (index date) to progression or death, whichever occurs first.; Patients will be censored for PFS by 31 December 2023; Progression of disease is based on scans and blood testing results. Comorbidity: Metabolic disease	01 Jan 2017 - 31 Dec 2023
PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Psychiatric disease	PFS is defined as the date of relapse or stage IV disease (index date) to progression or death, whichever occurs first.; Patients will be censored for PFS by 31 December 2023; Progression of disease is based on scans and blood testing results. Comorbidity: Psychiatric disease	01 Jan 2017 - 31 Dec 2023
PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Blood and lymphatic system	PFS is defined as the date of relapse or stage IV disease (index date) to progression or death, whichever occurs first.; Patients will be censored for PFS by 31 December 2023; Progression of disease is based on scans and blood testing results. Comorbidity: Blood and lymphatic system	01 Jan 2017 - 31 Dec 2023
OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Cardiac disease	OS is defined as the date of relapse or stage IV disease (index date) until death of any cause. - Patients will be censored for OS by 31 December 2023. Comorbidity: Cardiac disease	01 Jan 2017 - 31 Dec 2023
OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Vascular disease	OS is defined as the date of relapse or stage IV disease (index date) until death of any cause. - Patients will be censored for OS by 31 December 2023. Comorbidity: Vascular disease	01 Jan 2017 - 31 Dec 2023
OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Metabolic disease	OS is defined as the date of relapse or stage IV disease (index date) until death of any cause. - Patients will be censored for OS by 31 December 2023. Comorbidity: Metabolic disease	01 Jan 2017 - 31 Dec 2023
OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Psychiatric disease	OS is defined as the date of relapse or stage IV disease (index date) until death of any cause. - Patients will be censored for OS by 31 December 2023. Comorbidity: Psychiatric disease	01 Jan 2017 - 31 Dec 2023
OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Blood and lymphatic system	OS is defined as the date of relapse or stage IV disease (index date) until death of any cause. - Patients will be censored for OS by 31 December 2023. Comorbidity: Blood and lymphatic system	01 Jan 2017 - 31 Dec 2023

Collaborators and Investigators

• Sponsor: Pfizer
• Investigators: Study Director: Pfizer CT.gov Call Center, Pfizer

Publications and helpful links

Helpful Links

• To obtain contact information for a study center near you, click here.

Study record dates

Study Major Dates

• Study Start (Actual): March 11, 2024
• Primary Completion (Actual): April 19, 2024
• Study Completion (Actual): April 19, 2024

Study Registration Dates

• First Submitted: March 5, 2024
• First Submitted That Met QC Criteria: March 11, 2024
• First Posted (Actual): March 12, 2024

Study Record Updates

• Last Update Posted (Estimated): May 2, 2024
• Last Update Submitted That Met QC Criteria: April 30, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: Advanced Breast Cancer; Age; Palbociclib; Charlson Comorbidity Index (CCI); Denmark; First-line Treatment; Comorbidities; HR+/HER2-; Metastatic Breast Cancer (mBC); ICD10: C50; Hormone receptor positive / Human Epidermal growth factor Receptor 2 negative; Endocrine sensitive; Endocrine resistant; de novo mBC; Danish Breast Cancer Group (DBCG); Aromatase Inhibitor (AI); Real-World Evidence (RWE); Non-Interventional Study (NIS)
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Palbociclib
• Other Study ID Numbers: A5481188

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.